While body mass index is a good indicator for obesity, there are various other factors and clinical symptoms that need to be taken into account when diagnosing and treating a patient for obesity, explained Ted Kyle, RPh, MBA, principal at ConscienHealth.
While body mass index (BMI) can be a good indicator for obesity, there are various other factors and clinical symptoms that need to be taken into account when diagnosing and treating a patient for obesity, explained Ted Kyle, RPh, MBA, principal at ConscienHealth.
Transcript (slightly modified)
How much should BMI be taken into account when a patient is being diagnosed and treated for obesity?
BMI is one of these complicated things that is on the surface very simple. It’s a very useful screening tool, but when people think that BMI is the same thing as obesity, they’re mistaken. BMI is no more equivalent to obesity than a fever is to an infection. It’s a good sign. It’s a good easy sort of way to look for whether there might be a problem but obesity is really the excess of adipose tissue that accumulates and causes harm to health.
That excess visceral adipose tissue can be present at a fairly low BMI and actually cause quite a problem with health. It is more common at a high BMI, which is why BMI is used for a screening tool, but it’s only good as a screening tool. It’s not a diagnostic tool.
Can BMI be different among various ethnic groups?
Right, the cut points for different ethnic groups is different according to BMI. Again, BMI is just a rough indicator. What really matters is metabolically, how much metabolically active adipose tissue has accumulated around the visceral organs and how much is that harming health. There’s something called the Edmonton Obesity Staging System, which is a way of combining BMI with other clinical indicators to really give a good assessment of what someone’s disease state is.
Empowering Community Health Through Wellness and Faith
April 23rd 2024To help celebrate and recognize National Minority Health Month, we are bringing you a special month-long podcast series with our Strategic Alliance Partner, UPMC Health Plan. In the third episode, Camille Clarke-Smith, EdD, MS, CHES, CPT, discusses approaching community health holistically through spiritual and community engagement.
Listen
Data Back Neoadjuvant Combo vs Chemo Alone for Early-Stage NSCLC
April 24th 2024For patients with early-stage non–small cell lung cancer (NSCLC), combining neoadjuvant immune checkpoint inhibitors and platinum-based chemotherapy improves 2-year outcomes over chemotherapy alone, suggest findings of an extensive literature review and meta-analysis.
Read More
Overcoming Employment Barriers for Lasting Social Impact: Freedom House 2.0 and Pathways to Work
April 16th 2024To help celebrate and recognize National Minority Health Month, we are bringing you a special month-long podcast series with our Strategic Alliance Partner, UPMC Health Plan. Welcome to our second episode, in which we learn all about Freedom House 2.0 and the Pathways to Work program.
Listen
Polatuzumab Vedotin and R-CHP Appropriate for Untreated DLBCL
April 24th 2024Population pharmacokinetic and exposure-response analyses revealed a favorable benefit-risk profilane for the treatment combination of polatuzumab vedotin and rituximab, cyclophosphamide, doxorubicin, and prednisone (R-CHP).
Read More